KR20070045339A - Tricycles, their manufacture and use as pharmaceutical agents - Google Patents

Abstract

It is an object of the present invention to provide a compound of formula (I), a pharmaceutically acceptable salt thereof, enantiomeric forms, stereoisomers and racemates, the preparation of such compounds, medicaments comprising the same, and the preparation thereof, as well as of diseases such as cancer Use of such compounds in control or prevention.

Description

TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS}

The present invention relates to novel tricycles, methods for their preparation, pharmaceutical compositions comprising them, and their preparation, as well as the use of such compounds as pharmaceutically active agents.

Protein kinases regulate many different signaling processes by adding phosphate groups to proteins (Hunter, T., Cell 50 (1987) 823-829); In particular serine / threonine kinases phosphorylate the alcohol portion of the serine or threonine residues of the protein. The serine / threonine kinase family includes members that control cell growth, migration, differentiation, gene expression, muscle contraction, glucose metabolism, cellular protein synthesis and cell cycle regulation.

Aurora kinases are a family of serine / threonine kinases that are considered to play a major role in protein phosphorylation, which is essential for the completion of essential mitosis. The Aurora Kinase family consists of three main members: Aurora A, B and C (also known as Aurora-2, Aurora-1 and Aurora-3, respectively). Aurora-1 and Aurora-2 are described in US Pat. No. 6,207,401 to Sugen, and related patents and patent applications, for example EP 0 868 519 and EP 1 051 500.

For Aurora A, evidence continues to be that this is a new primary cancer gene. In most human tumor cell lines and primary colorectal tumors, breast tumors and other tumors, the Aurora A gene is amplified and transcription / protein is expressed a lot. Overexpression of Aurora A results in genetic instability, as shown by the marked increase in amplified centrosomes and aneuploidy, and transforms Ratl fibroblasts and mouse NIH3T3 cells in vitro. Aurora A-transformed NIH3T3 cells grow to tumors in nude mice (Bischoff, JR, and Plowman, GD, Trends Cell Biol. 9 (1999) 454-459; Giet, R., and Prigent, C, J. Cell Sci. 112 (1999) 3591-3601; Nigg, EA, Nat. Rev. Mol. Cell Biol. 2 (2001) 21-32; Adams, RR, et al., Trends Cell Biol. 11 (2001) 49-54) . Furthermore, amplification of Aurora A is associated with odd-drainploid and invasive clinical behavior (Sen, S., et al., J. Natl. Cancer Inst. 94 (2002) 1320-1329), and the amplification of the site in patients with nodular breast cancer (Isola, JJ., Et al., Am. J. Pathology 147 (1995) 905-911). For this reason, it is proposed that overexpression of Aurora A contributes to the cancer phenotype in association with chromosomal segregation and mitotic checkpoint control.

In human tumor cell lines lacking Aurora A, mitosis stops transcription. Thus, specific inhibition by selective inhibitors of aurora kinases is recognized to stop uncontrolled proliferation, reestablish mitotic checkpoint control, and lead to apoptosis of tumor cells. Thus, in xenograft models, Aurora inhibitors delay tumor growth and induce regression (Harrington, E.A., et al., Nat. Med. 10 (2004) 262-267).

Low molecular weight inhibitors for protein kinases are well known in the art. Such inhibitors for Aurora inhibition include, for example, quinazoline derivatives claimed in the following patents and patent applications: WO 00/44728; WO 00/47212; WO 01/21594; WO 01/21595; WO 01/21596; WO 01/21597; WO 01/77085; WO 01/55116; WO 95/19169; WO 95/23141; WO 97/42187; WO 99/06396; Pyrazole and triazole derivatives claimed in the following patents and patent applications: WO 02/22601; WO 02/22602; WO 02/22603; WO 02/22604; WO 02/22605; WO 02/22606; WO 02/22607; WO 02/22608; WO 02/50065; WO 02/50066; WO 02/057259; WO 02/059112; WO 02/059111; WO 02/062789; WO 02/066461; WO 02/068415; Pyrimidine derivatives: WO 03/077921; WO 03/078423; WO 03/078426; WO 03/078427; WO 04/000833 or imidazole, oxazole and thiazole derivatives: WO 02/96905; WO 04/005283;

However, to mention a few, there is still a need for new structural compounds with improved therapeutic properties such as enhanced activity, reduced toxicity, better solubility and improved pharmacokinetic profile.

The present invention relates to the use of a compound of formula (I) and all pharmaceutically suitable salts thereof for the manufacture of a medicament for the treatment of cancer:

[Formula I]

[Wherein R ¹ is hydrogen, alkyl or —C (O) -alkyl;

R ² is hydrogen, alkyl, cyano or halogen;

R ³ is hydrogen, alkyl, (C ₃ -C ₆ ) -cycloalkyl, alkoxy or alkylsulfanyl;

X is -C (O)-or -CH _2- ;

Y is -NH-, -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- ; here

R ⁴ is hydrogen or alkyl;

R ⁵ is hydrogen or alkyl, or alternatively

R ⁴ and R ⁵ together with the carbon atom to which they are attached form a cycloalkyl ring.

Another embodiment of the invention is the use for the preparation of a medicament for the treatment of cancer of a compound of formula (I):

Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Another embodiment of the invention is the use of a compound of formula I as an Aurora family kinase inhibitor:

Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Some tricycles or related compounds are described in US 4,835,280A, EP 0 189 103, US 4,954,498 and also Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; von der Saal, W., et al., J. Med. Chem. 32 (1989) 1481-1491; EP 0 318 902; DE 34 17 643; DE 36 42 315 and DE 37 01 277 are known as hemagglutination inhibitors. US 5,212,186 A describes related tricycles for the treatment of heart failure, hypertension and other diseases.

WO 03/035065 relates to kinase inhibitors, in particular benzimidazole derivatives as inhibitors for kinase insertion domain containing receptor (KDR) tyrosine kinases, spleen tyrosine kinases (SYK) and inducible T cell kinases (ITK).

The compounds according to the invention show activity as protein kinase inhibitors. Several diseases are associated with abnormal cellular responses caused by protein kinase mediated phenomena. Such diseases include autoimmune diseases, inflammatory diseases, nervous and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases. Therefore, considerable efforts have been made in the medical chemistry field to find effective protein kinase inhibitors as therapeutic agents.

The compounds according to the invention show in particular activity as Aurora family kinase inhibitors, in particular Aurora A kinase inhibitors, and thus may be useful for the treatment of diseases mediated by these kinases. Aurora A inhibition causes cell cycle arrest at the G2 stage of the cell cycle and exerts an antiproliferative effect in tumor cell lines. This means that Aurora A inhibitors are used for hyperproliferative diseases such as cancer, especially colorectal, breast, lung, prostate, pancreas, stomach, bladder cancer, ovary, melanoma, neuroblastoma, cervix, kidney or kidney cancer, leukemia or lymphoma. It may be useful for treatment. Treatment of acute-myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST).

It is an object of the present invention to provide a compound of formula (I) and a tautomer thereof, pharmaceutically suitable salts, enantiomeric forms, stereoisomers and racemates, their use as aurora kinase inhibitors, the preparation of such compounds, medicaments comprising the same and preparations thereof And also for use in the control or prevention of diseases of the compounds, in particular the diseases or dysfunctions mentioned above, or in the manufacture of the medicaments.

The term "alkyl" as used herein refers to saturated, straight or branched chain hydrocarbons containing 1 to 6, preferably 1 or 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 2 -Butyl, t-butyl. The alkyl is optionally substituted with one or more halogen atoms, preferably fluorine or chlorine, in particular fluorine. Preferably alkyl is substituted with such halogen 1 to 5 times, more preferably 1 to 3 times. Examples are trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl and the like, preferably trifluoromethyl. In one embodiment of the invention, only the "alkyl" groups used for R ³ are optionally substituted with halogen, while other "alkyl" groups used for R ¹ , R ² , R ⁴ and R ⁵ are not substituted with halogen. . In another embodiment of the invention all “alkyl” groups are unsubstituted with halogen.

The term "alkoxy" as used herein, means an alkyl group (alkyl-O-) as defined above, attached via an oxygen atom.

The term "alkylsulfanyl" as used herein, means an alkyl group as defined above (alkyl-S-) attached via a sulfur atom.

The term "cycloalkyl" as used herein, means a carboxyl unsaturated ring system comprising 3 to 6, preferably 3 to 5, carbon atoms. Such carboxylic unsaturated ring systems may be optionally substituted 1-3 times, preferably once or twice, in particular once with alkyl. Examples are cyclopropyl, 1-methyl-cycloprop-1-yl, cyclobutyl, cyclopentyl and cyclohexyl, preferably cyclopropyl. In an embodiment of the invention, the term "cycloalkyl" as used in R ³ is cyclopropyl. Cycloalkyl rings in which R ⁴ and R ⁵ form together with the carbon atoms to which they are attached are preferably cyclopentyl or cyclohexyl rings, in particular cyclopentyl rings.

The term "halogen" as used herein means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine, and more preferably fluorine and chlorine.

The compounds of formula I can exist in different tautomeric forms and various mixtures thereof. All tautomeric forms of the compounds of formula (I) and mixtures thereof are an object of the present invention. For example, the imidazole moiety of the tricyclic ring system of formula I can exist in two tautomeric forms as follows:

[Formula I]

Also for example, the pyrazole ring of formula I may form two tautomeric forms as follows:

.

.

In mass spectrometry (MS), the term "API +" as used herein refers to a positive atmospheric pressure ionization mode, the term "API-" refers to a negative atmospheric pressure ionization mode, and the term "ESI +" refers to a positive electrospray ionization mode.

An embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -CH _2- being].

An embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- .

An embodiment of the present invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -CH _2- ].

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -CH _2- ;

Y is -CR ⁴ R ^5- .

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- ;

Y is -CR ⁴ R ^5- .

Another embodiment of the invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -CH _2- ;

Y is -CR ⁴ R ^5- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -CH _2- ;

Y is -NH-, -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- ;

Y is -NH-, -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Yet another embodiment of the present invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -CH _2- ;

Y is -NH-, -CH ₂ -CR ⁴ R ^5-, or -R ⁴ R ⁵ -CH _2- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

Wherein X is -C (O)-.

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-.

Yet another embodiment of the present invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

Wherein X is -C (O)-.

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- being].

Another embodiment of the invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -C (O)-;

Y is -NH- or -CR ⁴ R ^5- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH- or -CR ⁴ R ^5- .

Yet another embodiment of the present invention provides an aurora of the compound of formula (I)

Use as a family kinase inhibitor:

[Wherein X is -C (O)-;

Y is -NH- or -CR ⁴ R ^5- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -C (O)-;

Y is -CR ⁴ R ^5- .

Yet another embodiment of the present invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Yet another embodiment of the present invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -C (O)-;

Y is -CR ⁴ R ^5- .

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein X is -C (O)-;

Y is -NH-.

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of a compound of formula (I) as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH-.

Another embodiment of the invention is the use of a compound of formula I as an Aurora family kinase inhibitor as follows:

[Wherein X is -C (O)-;

Y is -NH-.

A medicament comprising a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier is an object of the present invention and also includes one or more compounds of the present invention and / or pharmaceutically acceptable salts, if necessary, It is an object of the present invention to prepare a method comprising preparing one or more therapeutically valuable substances into a herbal dosage form with one or more therapeutically inert carriers.

Compounds of the present invention as well as pharmaceutically acceptable salts thereof in accordance with the present invention are useful for the control or prevention of diseases. Based on its aurora tyrosine kinase inhibition and its antiproliferative activity, the compounds are useful for the treatment of diseases such as cancer in humans or animals, and for the preparation of medicaments. Dosage varies depending on various factors such as the mode of administration, species, age and / or health of the individual.

Another embodiment of the invention is a combination of one or more compounds of formula (I) with a pharmaceutically acceptable adjuvant as an active ingredient for the treatment of diseases mediated by improper activity of Aurora family tyrosine kinases, in particular Aurora A tyrosine kinases. It is a drug containing.

Another embodiment of the present invention is a medicament comprising at least one compound of formula (I) together with a pharmaceutically acceptable adjuvant as an active ingredient for the treatment of cancer.

Another embodiment of the invention is for the treatment of colorectal, breast, lung, prostate, pancreas, stomach, bladder cancer, ovary, melanoma, neuroblastoma, cervix, kidney or renal cancer, leukemia or lymphoma And a pharmaceutically acceptable adjuvant, together with at least one compound of formula (I) as an active ingredient.

Another embodiment of the present invention provides a pharmaceutically acceptable adjuvant with at least one compound of formula (I) as an active ingredient for the treatment of acute-myeloid leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST) It is a drug containing together.

Another embodiment of the invention is the use of one or more compounds of formula (I) for the treatment of diseases mediated by inappropriate activity of Aurora family tyrosine kinases.

Another embodiment of the invention is the use of a compound of formula (I) as an Aurora A tyrosine kinase inhibitor as follows.

Another embodiment of the invention is the use of a compound of formula I as an antiproliferative agent.

Another embodiment of the invention is the use of one or more compounds of formula (I) for the treatment of cancer.

Another embodiment of the invention is the use of at least one compound of formula (I) for the manufacture of a medicament for the treatment of diseases mediated by inappropriate activity of aurora family tyrosine kinases.

Another embodiment of the invention is the use of at least one compound of formula (I) for the manufacture of a medicament for the treatment of cancer.

Another embodiment of the present invention, for the preparation of a medicament for treating direct colon, breast, lung, prostate, pancreas, stomach, bladder cancer, ovary, melanoma, neuroblastoma, cervix, kidney or kidney cancer, leukemia or lymphoma , At least one compound of formula (I).

Another embodiment of the invention is the use of at least one compound of formula I for the manufacture of a medicament for the treatment of acute-myeloid leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST). Another embodiment is a medicament comprising at least one compound of formula (I) together with a pharmaceutically acceptable adjuvant as an active ingredient for the treatment of diseases mediated by improper activity of Aurora family tyrosine kinases, in particular Aurora A tyrosine kinases. to be.

Another embodiment of the invention is a medicament comprising at least one compound of formula (I) together with a pharmaceutically acceptable adjuvant as an active ingredient for the treatment of cancer.

Another embodiment of the invention is an active ingredient for the treatment of colorectal, breast, lung, prostate, pancreas, stomach, bladder cancer, ovary, melanoma, neuroblastoma, cervix, kidney or kidney cancer, leukemia or lymphoma A medicament comprising at least one compound of formula I together with a pharmaceutically acceptable adjuvant.

Another embodiment of the present invention provides a pharmaceutically acceptable adjuvant with at least one compound of formula (I) as an active ingredient for the treatment of acute-myeloid leukemia (AML, acute lymphocytic leukemia (ALL) and gastrointestinal stromal tumor (GIST) It is a drug containing together.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

Provided that if R ¹ and R ² are hydrogen, X is —C (O) — and Y is —CR ⁴ R ⁵ —; Wherein R ⁴ and R ⁵ are methyl;

R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Yet another embodiment of the present invention is a compound of formula I:

Wherein R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- .

Yet another embodiment of the present invention is a compound of formula I:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- ;

Y is -CR ⁴ R ^5- .

Examples of such compounds are as follows:

7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -3,5,6,7-tetrahydro-imidazo [4,5-f] indole; And

1- [7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -6,7-dihydro-3H-imidazo [4,5-f] indol-5-yl] -Ethanone.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- ;

Y is -NH-, -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Yet another embodiment of the present invention is a compound of formula I:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Provided that if R ¹ and R ² are hydrogen, X is —C (O) — and Y is —CR ⁴ R ⁵ —; Wherein R ⁴ and R ⁵ are methyl;

R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Yet another embodiment of the present invention is a compound of formula I:

[Wherein, R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-.

Yet another embodiment of the present invention is a compound of formula I:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Examples of such compounds are as follows:

8,8-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5- g] quinolin-6-one; And

2- (5-isobutyl-2H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH-, -CR ⁴ R ^5- ;

Provided that if R ¹ and R ² are hydrogen, X is —C (O) — and Y is —CR ⁴ R ⁵ —; Wherein R ⁴ and R ⁵ are methyl;

R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ³ Is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH-, -CR ⁴ R ^5- .

Yet another embodiment of the present invention is a compound of formula I:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- ;

Provided that if R ¹ and R ² are hydrogen, X is —C (O) — and Y is —CR ⁴ R ⁵ —; Wherein R ⁴ and R ⁵ are methyl;

R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Yet another embodiment of the present invention is a compound of formula I:

[Wherein, R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Examples of such compounds are as follows:

2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

2- (5-methyl-2H-pyrazol-3-yl) -spiro [7,7-cyclopentan-5,7-dihydro-3H-imidazo [4,5-f] indol] -6-one ; Or 2- (5-methyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole according to current IUPAC nomenclature ] -6 (3H) -one;

2- (5-isobutyl-2H-pyrazol-3-yl) -spiro [7,7-cyclopentane-5,7-dihydro-1H-imidazo [4,5-f] indole] -6- On; Or 2- (5-isobutylyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f according to current IUPAC nomenclature ] Indole] -6 (3H) -one;

5-ethyl-7,7-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5,7,7-trimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; And

2- (5-isobutyl-2H-pyrazol-3-yl) -5,7,7-trimethyl-5,7-dihydro-3H-imidazo [4,5-f] indol-6-one.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH-.

Examples of such compounds are as follows:

6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazol-2-one;

3-methyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole-2 -On; And

3-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- 2-on.

Another embodiment of the invention is a compound of formula I as follows:

Wherein R ¹ is alkyl or -C (O) -alkyl.

Another embodiment of the invention is a compound of formula I as follows:

Wherein R ¹ is alkyl.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl; R ² is hydrogen or alkyl.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- .

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- .

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Examples of such compounds are as follows:

5-ethyl-7,7-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5,7,7-trimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On;

2- (5-isobutyl-2H-pyrazol-3-yl) -5,7,7-trimethyl-5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5,7,7-trimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5,7,7-trimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; Compounds with acetic acid;

5-isopropyl-7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On;

5-isopropyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On;

7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5-propyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ;

7,7-dimethyl-5-propyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

R ³ is alkyl substituted one or more times with halogen;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Examples of such compounds are as follows:

5-ethyl-7,7-dimethyl-2- (5-trifluoromethyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole- 6-one;

5-isopropyl-7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole -6-one;

7,7-dimethyl-5-propyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole- 6-one; And

5,7,7-trimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole-6- On.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

R ³ is alkoxy or alkylsulfanyl;

X is -C (O)-;

Y is -CR ⁴ R ^5- .

Examples of such compounds are as follows:

5-ethyl-2- (5-methoxy-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; And

5-ethyl-7,7-dimethyl-2- (5-methylsulfanyl-1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -CH ₂ -CR ⁴ R ⁵ -or -CR ⁴ R ⁵ -CH _2- .

Another embodiment of the invention is a compound of formula I as follows:

[Wherein, R ¹ is alkyl;

R ² is hydrogen or alkyl;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -C (O)-;

Y is -NH-.

Examples of such compounds are as follows:

3-methyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole-2 -On; And

3-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- 2-on.

Another embodiment of the invention is a compound of formula I as follows:

[Wherein R ¹ is —C (O) -alkyl;

R ² is hydrogen or alkyl;

R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl;

X is -CH _2- ;

Y is -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- .

Such compounds are for example as follows:

1- [7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -6,7-dihydro-3H-imidazo [4,5-f] indol-5-yl] -Ethanone.

Another embodiment of the invention is a medicament comprising as an active ingredient at least one compound of the formula (I) together with a pharmaceutically acceptable adjuvant:

[Wherein, R ¹ and R ² are hydrogen,

X is -C (O)-and Y is -CR ⁴ R ^5- ; Wherein R ⁴ and R ⁵ are methyl;

R ³ is hydrogen, (C ₂ -C ₆ ) alkyl or (C ₃ -C ₆ ) -cycloalkyl.

Another embodiment of the invention is a medicament comprising as an active ingredient at least one compound of the formula (I) together with a pharmaceutically acceptable adjuvant:

Wherein R ³ is hydrogen, (C ₂ -C ₆ alkyl, (C ₃ -C ₆ ) -cycloalkyl or fluorine],

Another embodiment of the invention is a medicament comprising as an active ingredient at least one compound of the formula (I) together with a pharmaceutically acceptable adjuvant:

Wherein R ¹ is alkyl or -C (O) -alkyl.

Another embodiment of the invention is a medicament comprising as an active ingredient at least one compound of the formula (I) together with a pharmaceutically acceptable adjuvant:

Wherein R ¹ is alkyl.

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of one of the following compounds:

7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -3,5,6,7-tetrahydro-imidazo [4,5-f] indole;

1- [7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -6,7-dihydro-3H-imidazo [4,5-f] indol-5-yl] Ethanone;

8,8-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

2- (5-isobutyl-2H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

2- (5-methyl-2H-pyrazol-3-yl) -spiro [7,7-cyclopentan-5,7-dihydro-3H-imidazo [4,5-f] indol] -6-one ; Or 2- (5-methyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole according to current IUPAC nomenclature ] -6 (3H) -one;

2- (5-isobutyl-2H-pyrazol-3-yl) -spiro [7,7-cyclopentane-5,7-dihydro-1H-imidazo [4,5-f] indole] -6- On; Or 2- (5-isobutyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] according to current IUPAC nomenclature Indole] -6 (3H) -one;

6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazol-2-one;

2- (4,5-dimethyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

7,7-dimethyl-2- [5- (3-methyl-butyl) -1H-pyrazol-3-yl] -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On;

2- (5-ethyl-4-methyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ;

7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

2- (5-cyclopropyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

2- (5-isopropyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one;

8,8-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

8,8-dimethyl-2- (1H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

2- (5-cyclopropyl-1H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

2- (5-isopropyl-2H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one;

2- (2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentan-1 ', 7-imidazo [4,5-f] indole] -6 (3H) -one;

2- (5-isopropyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H )-On;

2- (5-propyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H) -On;

7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-lH-imidazo [4,5-f] indol-6-one; And

2- (5-cyclopropyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ′, 7-imidazo [4,5-f] indole] -6 (3H )-On.

Another embodiment of the invention is the use for the manufacture of a medicament for the treatment of cancer of one of the following compounds:

3-methyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole-2 -On;

3-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- 2-one;

5-ethyl-7,7-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5,7,7-trimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On;

2- (5-isobutyl-2H-pyrazol-3-yl) -5,7,7-trimethyl-5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5,7,7-trimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5,7,7-trimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one;

5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; Compounds with acetic acid;

5-isopropyl-7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On;

5-isopropyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On;

7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5-propyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ;

7,7-dimethyl-5-propyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ;

5-ethyl-7,7-dimethyl-2- (5-trifluoromethyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole- 6-one;

5-isopropyl-7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole -6-one;

7,7-dimethyl-5-propyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole- 6-one;

5,7,7-trimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole-6- On;

5-ethyl-2- (5-methoxy-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; And

5-ethyl-7,7-dimethyl-2- (5-methylsulfanyl-1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On;

Another embodiment of the invention provides a process for the preparation of a compound of formula (I)

Wherein R ¹ is alkyl or -C (O) -alkyl;

a) with a compound of Formula II:

[Formula II]

Wherein R ¹ is alkyl or —C (O) -alkyl, X and Y are as defined in formula (I) above,

By reacting a compound of formula III:

[Formula III]

[Wherein A is -OH, -Cl, -H or -OMe,

R ² and R ³ are the same as defined in Formula I above],

Provided is a compound of Formula I:

[Formula I]

[Wherein R ¹ is alkyl or —C (O) -alkyl,

R ² , R ³ , X and Y are the same as defined in formula I above],

b) isolating the compound of formula I from the reaction mixture,

c) if necessary, converting it to a pharmaceutically acceptable salt.

The compounds of formula (I), or pharmaceutically acceptable salts thereof, which are the subject of the present invention, can be prepared via any method known to be applicable to the preparation of chemically related compounds. Such methods used in the preparation of compounds of formula (I) or pharmaceutically acceptable salts thereof are the following Schemes 1 and 2 and Examples (unless otherwise indicated, X, Y, R ¹ , R ² and R ³ are as defined above) It is explained in). Necessary starting materials can be obtained through standard processes of organic chemistry. The preparation of such starting materials is described in the accompanying examples. Alternative starting materials required are obtainable through similar processes described within the ordinary skill of the organic chemist.

Benzimidazole ring systems of formula (I) are similar to the methods described in the literature, but can be formed via different synthetic routes (Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; DE 35 31 678).

One route for the preparation of compounds of formula I (Scheme 1) starts from the diamines of formula II, carboxylic acids (A is a compound of formula III wherein A is OH), acid chloride (A is Cl) aldehyde (A is H ), Methyl carboxylate (A is OMe) or activating ester (A is for example hydroxybenzotriazole). See the above document for detailed procedures.

Scheme 1

Pyrazoles of formula III are commercially available or they are standard processes of organic chemistry (see for example Stanovnik, B., and Svete, J., Science of Synthesis 12 (2002) 15-225), for example 1,3 Condensation of dicarbonyl compounds with hydrazine (see, eg, WO 04/032928 or van Herk, T., et al., J. Med. Chem. 46 (2003) 3945-3951), or diazo compounds and acetylene 1,3-bipolar cycloaddition (see, eg, Sewald, N., et al., Liebigs Ann. Chem. (1992) 947-952). Pyrazoles of formula III wherein R ³ is alkoxy are selected from 5-hydroxy-pyrazole-3-carboxylic acid esters (Ochi, H., et al., Chem. Pharm. Bull. 31 (1983) 1228-1234 ) Can then be prepared through alkylation of an alkylhalogenide with a 5-hydroxy group in the presence of a base such as cesium carbonate in a solvent such as dimethylformamide (DMF), N-methyl-pyrrolidone (NMP) (See, eg, WO 03/035065), or Martins, MAP, et al., And may be provided according to the process of Synthesis 15 (2003) 2353-2357. And pyrazoles of formula III, wherein R ³ is alkylsulfanyl, can be prepared via the corresponding oxo-ketene dithioacetal according to Mahata, PK, et al., Tetrahedron 59 (2003) 2631-2639. Alternatively to Scheme 1, the 5-alkoxy- or 5-alkylsulfanyl-pyrazole moiety of the compound of formula I, wherein R ³ is alkoxy or alkylsulfanyl, is a different reaction step as described in WO 03/035065. It may be introduced in the order of.

The pyrazoles of formula III, wherein R ² is hydrogen, R ³ is trifluoromethyl and A is hydroxy, can be prepared in a three step process according to scheme 1a: 4,4,4 under acidic conditions Condensation of -trifluoro-1- (2-furyl) -1,3-butanedione with benzyl hydrazine, oxidative decomposition of the furan ring to a carboxylic acid functional group using potassium permanganate (see, for example, Djuric, SW, et al., J. Med. Chem. 43 (2000) 2975-2981; Jia, ZJ., Et al., Bioorg.Med. Chem. Lett. 12 (2002) 1651-1655 or Pruitt, JR, et al., J. Med Chem. 46 (2003) 5298-5315) and cleavage of benzyl protecting groups can provide the required 5-trifluoromethyl-2H-pyrazole-3-carboxylic acid.

Scheme 1a

This process in which N-benzyl or alternatively p-methoxybenzyl groups are used as intermediate protecting groups (Subramanyam, C, Synth. Commun. 25 (1995) 761-774) is also used for the preparation of other pyrazoles required as starting materials. Can be applied.

Compounds of formula II wherein X is -C (O)-, R ¹ is hydrogen or alkyl, and Y is -CR ⁴ R ⁵ or -NH- are Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; von der Saal, W., et al., J. Med. Chem. 32 (1989) 1481-1491; DE 34 17 643; It may be prepared in a manner similar to that described in EP 0 318 902, US 4,666,923A, US 4,695,567A, US 4,863,945A and US 4,985,448A. Compound of formula II wherein X is -C (O)-or -CH _2- , R ¹ is hydrogen or -C (O) alkyl, and Y is -CR ⁴ R ⁵ -is DE 36 42 315 It can be prepared according to. In addition, compounds of formula II wherein X is -C (O)-or -CH _2- , R ¹ is hydrogen or alkyl, and Y is -CR ⁴ R ⁵ -CH ₂ -or -CH ₂ -CR ⁴ R ^5- ) is described in DE 37 01 277.

For example, the diamine of formula II, wherein X is -C (O)-, R ¹ is hydrogen or alkyl, and Y is -CR ⁴ R ⁵ , is designated IIa and as shown in Scheme 1b. US 4,666,923A, DE 34 10 168 and Mertens, A., et al., J. Med. Chem. It may be synthesized according to 30 (1987) 1279-1287:

Scheme 1b

In Scheme 1b, R ¹ , R ⁴ and R ⁵ have the same meanings as given in the above formula (I), and L represents a leaving group such as iodine, bromine, chlorine, triflate and the like.

In an alternative process the diamines of formula IIa (wherein R ¹ is alkyl) are diamines of formula IIb (X is —C (O) —, R ¹ is hydrogen, and Y is hydrogen, as shown in Scheme 1c). via alkylation of the -CR ⁴ R ⁵ a compound ⅱ Im) it can be obtained.

Scheme 1c

Diamines of formula (IIb) may be synthesized according to Scheme 1b, omitting step 5.

Another synthesis of the compounds of formula (I) starts with (nitrogen 2) nitro compounds IV or V, which are then hydrogenated and then cyclized with the desired benzimidazole derivatives together with acetic acid or hydrochloric acid. Detailed processes are described in Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287; See DE 35 31 678.

Scheme 2

Compounds of Formulas IV and V, wherein X is C (O), R ¹ is hydrogen or alkyl, and Y is -CR ⁴ R ⁵ , -NH-; Mertens, A., et al., J. Med . Chem. 30 (1987) 1279-1287; von der Saal, W., et al., J. Med. Chem. 32 (1989) 1481-1491; DE 34 17 643; It may be prepared in a manner similar to that described in EP 0 318 902. Compounds of formulas IV and V wherein X is C (O) or -CH _2- , R ¹ is hydrogen or -C (O) alkyl, and Y is -CR ⁴ R ^5- Can be prepared according to DE 36 42 315. Furthermore a compound of formula II wherein X is C (O) or -CH _2- , R ¹ is hydrogen or alkyl, and Y is -CR ⁴ R ⁵ -CH ₂ -or -CH ₂ -CR ⁴ R ⁵ -Is described in DE 37 01 277.

The compounds according to the invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to conventional acid addition salts which retain the biological effectiveness and properties of the compounds of formula (I), which are formed from suitable non-toxic organic or inorganic acids. Sample acid addition salts are those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and organic acids such as p-toluenesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid , Ethanesulfonic acid and the like. Chemical modification of pharmaceutical compounds (eg, drugs) to salts is a technique known to pharmacists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of the compounds. See, eg, Stahl, P. H., and Wermuth, G., (editors), Handbook of Pharmaceutical Salts, Verlag Helvetica Chimica Acta (VHCA) Zurich, (2002) or Bastin, R.J., et al., Organic Proc. Res. Dev. 4 (2000) 427-435.

The compound of formula (I) may comprise one or a plurality of chiral centers, which may exist in racemate or optically active form. The racemates can be separated into enantiomers according to known methods. For example, diaisomeric salts which can be separated by crystallization are formed from optically active acids such as D- or L-camphorsulfonic acid and racemic mixtures. Alternatively, separation of the enantiomers may be accomplished using chromatography on commercially available chiral HPLC-phases.

Pharmacological activity

Compounds of formula (I) and their pharmaceutically acceptable salts have important pharmacological properties. The compound shows activity as an inhibitor of the Aurora Kinase family and also shows antiproliferative activity. As a result, the compounds of the present invention are useful for the treatment and / or prophylaxis of diseases due to overexpression of the known aurora family, preferably the kinase of Aurora A, in particular for the treatment and / or prophylaxis of such diseases. The activity of the compounds as inhibitors of the aurora kinase family is confirmed by the following biological assays:

Aurora A of  For inhibitors IC ₅₀  of  Measure

(96 MTP-ELISA)

Assay Principle

Aurora A is a serine threonine kinase involved in spindle aggregation and chromosome segregation.

This assay is typically an ELISA-type assay in which a biotinylated substrate (PKB-GSK2) is phosphorylated. Phosphorylation was performed on peroxidase (POD) labeled polyclonal antibodies (PAK <M-Ig> S-IgG-POD) and phosphopeptide monoclonal antibodies (Mab) (MAK <P-GSK> M-27E5-IgG) Is detected. This assay is IC ₅₀ Valid for measurement.

material

Assay plates 96-well polystyrene plates, stereptavidin-coated,

10 mM in sample dimethylsulfoxide (DMSO)

Aurora A-His-4 C-terminal Histidine ₄ (His ₄ ) -tagged Aurora A

Full length protein, stock solution 0.7 mg / ml,

Final concentration: 250 ng / ml

Biotinylated peptide (Biotin-SGRARTSSFAEPGG-CONH ₂ ) derived from PKB-GSK2 human GSK3-alpha sequence,

Stock solution 600 μM, final concentration: 200 nM

PAK <M-Ig> S-IgG-POD anti-mouse IgG, horseradish peroxidase (HRP)-

Linked antibody, diluted in 3% BSA / PBS-T (1: 10000),

(Cell Signaling, Cat.No .: 7076)

MAK <P-GSK> M-27E5-IgG Phospho-GSK-3-alpha (Ser 21) (27E5) Monoclonal

Antibody, stock solution l.85 mg / ml, diluted in 3% BSA / PBS-T (1: 6000), final concentration: 0.31 μg / ml,

(Cell Signaling, Cat.No .: 9337B)

ATP adenosine-5'-triphosphate 1 mM, diluted in kinase buffer, (Roche Diagnostics GmbH, Cat. No .: 127531-001,), final concentration: 4 μΜ

TRIS 2-amino-2-hydroxymethyl-1,3-propanediol

("tris- (hydroxymethyl) -aminomethane")

(MERCK, Cat.No .: 108382.2500)

BSA bovine serum albumin fraction V, no fatty acids (Roche Diagnostics GmbH, Cat. No. 9100221)

EDTA Titriplex III (di-sodium-EDTA dihydrate),

120 mM, (MERCK, Cat.No .: 1.08418.1000)

ABTS buffer ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)) 16.7 mg / ml (Roche Diagnostics GmbH, Cat.No .: 1204530)

ABTS tablets 50 ml working solution of one ABTS tablet

Soluble in (ABTS buffer) (Roche Diagnostics GmbH, Cat.No .: 1112422)

Tween 20 Polysorbat 20 (Roche Diagnostics GmbH, Cat.

No .: 10006394-001)

DTT 1,4-dithiothreitol (Roche Diagnostics GmbH, Cat.No .: 197777)

MgCl ₂ x 6H ₂ O MERCK, Cat. No .: 105833.1000

Kinase Buffer 50 mM TRIS, 10 mM MgCl ₂ , 1 mM DTT,

0.1% Tween 20, pH 7.8

PBS-T (= wash buffer) (PBS-T) 10 g / l PBS (phosphate buffered saline) and 0.033% Tween 20

3% BSA / PBS-T 3% BSA dissolved in PBS-T

Way

This assay is performed in 96-well format, 100 μl incubation volume and the following plate layout for IC ₅₀ measurements in 5 samples (8 concentrations each made from twofold testing):

NC negative control, no ATP, 1% DMSO

In PC positive control ATP, 1% DMSO

Control with S ATP, 1% DMSO, final concentration: a = 100 μM, b = 20 μM, c = 4 μM, d = 0.8 μM, e = 0.16 μM, f = 0.032 μM, g = 0.0064 μM,

h = 0.00128 μM

Step / run

1. Sample Preparation: Samples diluted in kinase buffer are added to assay plates in 24 μl per well (descending sequence) (final concentration, DMSO 1%).

2. Add 16 μl Aurora-A-his-4 diluted in kinase buffer directly to assay plates.

3. Add 40 μl PKB-GSK2 / ATP mixture per well directly to assay plate (final concentration: Aurora A = 250 ng / ml, GSK2 = 200 nM, ATP = 4 μM). Negative Control: No ATP.

4. Incubate assay plates at room temperature for exactly 90 minutes.

5. Add 20 μl EDTA to all wells to stop the reaction.

6. Wash assay plates 3 × with 200 μl wash buffer per well.

7. 100 μl MAK <P-GSK> M27E5-IgG (1: 10000) and PAK <M-Ig> S-IgG-POD (1: 6000) dissolved in 3% BSA / PBS-T were added to the assay plate. Add 100 μl per well.

8. Incubate assay plates for 60 minutes at room temperature.

9. Wash assay plates 3 × with 200 μl wash buffer per well.

10. Add 100 μl ABTS solution per well to the assay plate and incubate in MTP shaker at room temperature for about 4 minutes.

11. Measure the absorption at 405/492 nm.

12. Percent inhibition is measured as follows:

(I- (E _Sample -E _NC ) / (E _PC -E _NC )) X 100

13. Calculate IC ₅₀ using non-linear curve fit (XL feet software (ID Business Solution Ltd., Guilford, Surrey, UK))

Results: Table 1

Antiproliferative  activation

The following biological assays confirm the activity of the compounds as antiproliferative agents:

HCT  At 116 cells Celltiter - Glo ™ Assay

CellTiter-Glo ™ Luminescent Cell Viability Assay (Promega) is a uniform method of measuring the number of viable cells through quantification of ATP present in culture, which indicates the presence of active metabolic cells.

HCT 116 cells (human colon carcinoma, ATCC-No. (FBS)); Incubated with 100 units / ml penicillin / 100 μg / ml streptomycin (= Pen / Strep, Invitrogen Cat. No. 15140). Cells were seeded in 384 well plates for assay and 1000 cells per well in the same culture. Next day test compounds were added at various concentrations ranging from 30 μM to 0.0015 μM (10 concentrations, diluted 1: 3). After 5 days, CellTiter-Glo ™ assay was performed according to the instructions in the instructions (CellTiter-Glo ™ Luminescent Cell Viability Assay, Promega). Briefly, the cell-plates were equilibrated for about 30 minutes at room temperature and then CellTiter-Glo ™ reagent was added. The contents are carefully mixed for 15 minutes to induce cell lysis. After 45 luminescence signals were measured on Victor 2, (Scanning Multiwell Spectrophotometer, Wallac).

The details:

first day:

Cultures: RPMI 1640, 5% FCS (Sigma Cat.-No. F4135), Pen / Strep (Invitrogen, Cat No. 15140) with GlutaMAX ™ I (Invitrogen, Cat-Nr. 61870).

HCT 116 (ATCC-No. CCl-247): 1000 cells in 60 μl per well in 384 well plates (Greiner 781098, μClear-plate white)

After inoculation, the plates are incubated at 37 ° C., 5% CO ₂ for 24 hours.

Day 2: Trigger (treatment with compound, 10 concentrations):

3.5 μl of 10 mM compound stock solution was added directly to 163 μl culture to achieve a final concentration of 30 μM as the highest concentration. Thereafter, step e) of the following dilution process was carried out.

In order to achieve from the second highest concentration to the lowest concentration, it was then serially diluted in a dilution step of 1: 3 according to the following process (a-e).

a) Add 10 μl of stock solution of 10 mM compound to 20 μl dimethylsulfoxide (DMSO) for the second highest concentration.

b) Dilute 8x 1: 3 (always 10 μl to 20 μl DMSO) in this DMSO dilution row (to 9 wells at a concentration of 3333.3 μM to 0.51 μM).

c) Dilute each concentration to 1: 47.6 (diluted 3.5 μl compound in 163 μl culture).

e) 10 μl of all concentrations are added to 60 μl culture in cell plates to make a final concentration of DMSO at 0.3% for all wells and 10 final concentrations of compound ranging from 30 μM to 0.0015 μM.

Each compound is tested three times.

Incubate at 37 ° C., 5% CO ₂ for 120 hours (5 days).

analysis

-30 μl CellTiter-Glo ™ reagent (prepared from CellTiter-Glo ™ buffer and CellTiter-Glo ™ substrate (freeze dried) purchased from Promega) was added per well,

Shaking at room temperature for 15 minutes,

Incubate without shaking at room temperature for an additional 45 minutes.

Measure :

Victor 2 Scanning Multiwell Spectrophotometer (Wallac), Luminescence Mode (0.5 sec / read, 477 mm)

Nonlinear curve fit (XL feet software (ID Business Solution Ltd., Guilford, Surrey, UK)) is measured using IC _5O .

Significant inhibition of HCT 116 cell viability was detected in all compounds, exemplified by the compounds shown in Table 1.

Results: Table 2

The compounds according to the invention and their pharmaceutically acceptable salts can be used in the form of medicaments, for example pharmaceutical compositions. The pharmaceutical compositions can be administered, for example, in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions. Dosing can however also be effected, for example, rectally in the form of suppositories, or parenterally in the form of injection solutions.

Such pharmaceutical compositions can be obtained by processing the compounds according to the invention with pharmaceutically inert, inorganic or organic carriers. As such carriers for tablets, coated tablets, dragees and hard gelatin capsules, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used. Carriers for soft gelatin capsules include, for example, vegetable oils, waxes, fats, semisolid and liquid polyols and the like. Depending on the nature of the active substance, no carrier is necessary, mainly in the case of soft gelatin capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical compositions may include preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, pigments, flavoring agents, salts for controlling osmotic pressure, buffer masking agents or antioxidants. It may also include other therapeutically valuable substances.

Pharmaceutical compositions include, for example:

a) tablets Formulation  (Wet Granulation ):

Manufacture process:

1. Mix items 1, 2, 3 and 4 and granulate with purified water.

2. Dry the granules at 50 ° C.

3. Pass the granules through a suitable grinding apparatus.

4. Add item 5 and mix for 3 minutes; Compress in a suitable compressor.

b) capsule formulation :

Manufacture process:

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.

2. Add items 4 and 5 and mix for 3 minutes.

3. Fill into a suitable capsule.

c) micro suspension

1. Weigh 4.0 g glass beads on custom-made tube GL 25, 4 cm (beads fill half of tube).

2. Add 50 mg compound and disperse with spatrum and vortex.

3. Add 2 ml gelatin solution (weight beads: gelatin solution = 2: 1) and vortex.

4. Cover and cover with aluminum foil to shade.

5. Prepare the counter balance for the grinder.

6. Grind at 20 / s for 4 hours in a Retsch grinder (30 / s for up to 24 hours for some materials).

7. Extract the suspension from the beads by centrifugation for 2 min at 400 g using a two-layer filter (100 μm) connected to the collection bottle on the filter holder.

8. Transfer the extract to the measuring cylinder.

9. Repeat the wash in small volumes (here 1 ml step) until the final volume is reached or until the extract is clear.

10. Fill with gelatin and homogenize to final volume.

The following examples and references are provided to aid the understanding of the present invention, the true scope of which is defined in the appended claims. It is understood that modifications can be made to the process as defined without departing from the spirit of the invention.

A: starting material

5,6- Diamino -1-ethyl-3,3-dimethyl-1,3- Dehydro Preparation of Indole-2-one

i) 1-ethyl-3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one

A solution of 3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one (6 g, 29.10 mmol) in anhydrous N, N-dimethylformamide (DMF) (35 ml) was dissolved in sodium hydroxide. Treated with. The resulting suspension was stirred at 60 ° C. for 1 hour. A solution of bromoethane (2.17 ml, 3.17 g, 29.10 mmol) in DMF (10 ml) was added. The mixture was left to cool to rt and stirred for 1 h. After removal of the solvent, the mixture was quenched with water (100 ml) and extracted with ethyl acetate (3 x 100 ml). The extract was dried over Na ₂ SO ₄ , evaporated and the crude product was purified by silica gel column chromatography. Elution with ethyl acetate / n-heptane (1: 3) gave 5.94 g (87%) of a yellow solid.

Ii) 6-amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one

1-ethyl-3,3-dimethyl-6-nitro-1,3-dihydro-indol-2-one (5.9 g, 25.19 mmol) in methanol / tetrahydrofuran (THF) (1: 1, 80 ml) Pd / C (10%, 1.2 g) was added to the solution of and hydrogenated into the mixture at room temperature for 4 hours. After filtration and evaporation of the solvent 5.05 g (98%) 6-amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one was isolated as a white solid.

Iii) N- (1-ethyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl) -acetamide

A solution of 6-amino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one (5.05 g, 24.72 mmol) in acetic anhydride (80 ml) was stirred at room temperature for 4 hours. . The mixture was poured into ice water (150 ml) and left to warm to room temperature and stirred again for 2 hours. After extraction with ethyl acetate (3 x 100 ml), the combined organic layers were washed with saturated NaHCO ₃ -solution (3 x 100 ml), brine (100 ml) and dried over sodium sulfate. After removal of the solvent the crude product was purified by silica gel column chromatography (ethyl acetate / n-heptane 1: 1) to give 5.6 g (91%) N- (1-ethyl-3,3-dimethyl-2-oxo-2, 3-dihydro-1H-indol-6-yl) -acetamide was obtained as a pale yellow solid.

Iii) N- (1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-6-yl) -acetamide

Of N- (1-ethyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl) -acetamide (5.6 g, 22.73 mmol) in acetic anhydride (70 ml) To the solution was added nitric acid (100%, 1.96 g, 1.29 ml, 31.2 mmol) at 0 ° C. The mixture was stirred for 30 minutes and then poured into cold water (150 ml). After stirring for 4 hours, the mixture was extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with sodium hydroxide solution (1M, 100 ml) and water (100 ml), dried over sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography (ethyl acetate / n-heptane 1: 1) to 5.2 g (78%) N- (1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2, 3-dihydro-1H-indol-6-yl) -acetamide was obtained as a yellow solid.

v) 6-amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indol-2-one

N- (1-ethyl-3,3-dimethyl-5-nitro-2-oxo-2,3-dihydro-1H-indol-6-yl) -acetamide (5.2 g, 17.85 mmol) was added to ethanol (40 ml). After addition of hydrochloric acid (25%, 8 ml, 81.44 mmol), the mixture was stirred at reflux for 3 hours. The reaction mixture was left to cool to room temperature and then quenched with water (80 ml). The yellow precipitate was isolated by suction and washed with ethanol / water (1: 1). The solid is dissolved in ethyl acetate, dried over sodium sulfate and concentrated to 4.15 g (93%) 6-amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indole-2 -One was obtained as an orange solid.

vi) 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one

PtO ₂ (0.4) in a solution of 6-amino-1-ethyl-3,3-dimethyl-5-nitro-1,3-dihydro-indol-2-one (4.15 g, 16.65 mmol) in ethanol (80 ml) g) was added and hydrogenated into the mixture at room temperature for 3.5 hours. After filtration and evaporation of the solvent, 3.25 g (89%) 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one was obtained as an orange solid. .

5,6- Diamino -1,3,3- Trimethyl -1,3- Dehydro Preparation of Indole-2-one

5,6-diamino-1,3,3-trimethyl-1,3-dihydro-indol-2-one to 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-di Prepared similarly to the 6-step-synthesis described for hydro-indol-2-one.

5,6- Diamino -3,3-dimethyl-1-propyl-1,3- Dehydro Preparation of Indole-2-one

5,6-diamino-3,3-dimethyl-1-propyl-1,3-dihydro-indol-2-one to 5,6-diamino-1-ethyl-3,3-dimethyl-1,3 Prepared similarly to the 6-step-synthesis described for -dihydro-indol-2-one.

5,6- Diamino -1-isopropyl-3,3-dimethyl-1,3- Dehydro Preparation of Indole-2-one

5,6-diamino-3,3-dimethyl-1-isopropyl-1,3-dihydro-indol-2-one to 5,6-diamino-1-ethyl-3,3-dimethyl-1, Prepared similarly to the 6-step-synthesis described for 3-dihydro-indol-2-one.

5- Trifluoromethyl -2H- Pyrazole -3- Carboxylic acid  Produce

i) 1-benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole

50 g (0.240) solution of 4,4,4-trifluoro-1- (2-furyl) -1,3-butanedione in 24 ml (0.024 mol) of 1M hydrogen chloride solution in ethanol and further in 520 ml of EtOH. mol) 50 g (0.248 mol) benzylhydrazine dihydrochloride was added in small portions at room temperature. The reaction mixture was then heated to reflux for 7 hours. After cooling to room temperature, the reaction mixture was neutralized with saturated NaHCO ₃ , EtOH was distilled off and the remaining oil / water mixture was extracted with 300 ml dichloromethane. The organic phase is washed twice with 100 ml water, dried over Na ₂ SO ₄ and concentrated in vacuo to give 73.7 g 1-benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole as a brown oil. Was obtained and used for the next reaction without purification. MS: M = 293.0 (API +)

Ii) 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid

To 9.5 g (0.0325 mol) of a solution of 1-benzyl-5-furan-2-yl-3-trifluoromethyl-1H-pyrazole in 3O ml acetone, add 27.2 g (0.172 mol) of potassium permanganate in 450 ml water. Added. The reaction mixture was heated at 60 ° C for 4 h. After cooling to room temperature, 200 ml 2-propanol were added and stirred overnight, which was filtered through a pad of celite and washed with 1 1 acetone. The filtrate was concentrated in vacuo to 150 ml. The residue was dissolved in 20 ml 2M NaOH and 150 ml water. The resulting aqueous phase was washed twice with 70 ml ethyl ether and then acidified with 30 ml 5M HCl solution. The suspension was extracted with 200 and 50 ml ethyl acetate (EtOAc). The combined organic extracts were washed with 30 ml water and 5 ml brine and concentrated. The residue was purified by silica gel chromatography to give 6.1 g (0.022 mol, 67%) of 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxyl (CH ₂ Cl ₂ with 1% acetic acid). The acid was obtained as a near white solid. MS: M = 271.1 (ESI +)

Viii) 5-trifluoromethyl-2H-pyrazole-3-carboxylic acid

About 50 ml ammonia was condensed into a three-necked flask in an ethanol-dry ice bath and 100 mg (3.70 mmol) 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid was added. A small amount of sodium solution was added (about 260 mg, 11.3 mmol) until blue appeared in the solution and maintained for more than 5 minutes. Ammonia was evaporated overnight. Water was added and acidified with 2N HCl solution. The aqueous phase was extracted twice with ethyl acetate, the combined organic phases were dried over Na ₂ SO ₄ and the solvent was evaporated in vacuo to 560 mg (3.11 mmol, 84%) 5-trifluoromethyl-2H-pyrazole-3 -Carboxylic acid was obtained as a yellow solid, which was used without further purification. MS: M = 179.0 (API-)

5- Methoxy -1H- Pyrazole -3- Carboxylic acid  Ethyl ester

5-hydroxy-1H-pyrazole-3-carboxylic acid ethyl ester (300 mg, 1.92 mmol) is dissolved in anhydrous N, N-dimethylformamide (DMF) (35 ml) and cesium carbonate (626 mg, 1.92 mmol) was added. The resulting suspension was treated with iodomethane (120 μl, 273 mg, 1.92 mmol) and stirred at rt for 12 h. The reaction mixture was quenched with saturated potassium hydrogen sulfate solution and extracted with ethyl acetate (3 × 100 ml). The combined organic layer was washed with water (50 ml) and brine (50 ml). The extract was dried over sodium sulfate, evaporated and the crude product was purified by silica gel column chromatography. Elution with ethyl acetate / n-heptane (1: 3) gave 124 mg (38%) of a white solid.

5- Methoxy -1H- Pyrazole -3- Carboxylic acid

5-methoxy-1H-pyrazole-3-carboxylic acid ethyl ester (120 mg, 0.71 mmol) was dissolved in tetrahydrofuran (THF) (2 ml). After addition of sodium hydroxide (2M in water, 1 ml), the mixture was stirred at reflux for 2 hours. The reaction mixture was cooled to room temperature, acidified by addition of hydrochloric acid (pH 3) and extracted with ethyl acetate (3 × 20 ml). The extract was dried over sodium sulfate and evaporated to give 86 mg (86%) of a white solid.

2- (3,3- Vis - Methylsulfanyl -Acryloyl) -5-ethyl-7,7-dimethyl-5,7- Dehydro -1H- Imidazo [4,5-f] indole Preparation of -6-one

(i) 5-ethyl-2- (1-hydroxy-ethyl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one

5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one (10 g, 46 mmol) in HCl (100 ml, 4N), 2-hydroxy- A mixture of propionic acid (9.13 g, 91.2 mmol) was refluxed for 16 hours. After cooling, neutralized with aqueous ammonia (25%), stirred for 1.5 hours, the precipitate was filtered off and dried in vacuo at 50 ° C. to give 12.29 g (95%) of a gray solid.

(Ii) 2-acetyl-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indole-6-one

5-ethyl-2- (1-hydroxy-ethyl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one (13 g, 47.6 mmol ) And manganese (IV) dioxide (16.54 g, 190 mmol) were suspended in chloroform (400 ml) and stirred at 65 ° C. for 16 h. The mixture was cooled, filtered through celite, and the filtrate was concentrated in vacuo to afford 11.6 g (90%) of a beige solid.

(Iii) 2-acetyl-5-ethyl-7,7-dimethyl-1- (tetrahydro-pyran-2-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole- 6-on

2-acetyl-5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one (11.7 g, 43.1 mmol) and p-toluenesulfonic acid Monohydrate (0.82 g, 4.3 mmol) was dissolved in dichloromethane (200 ml). To this solution was added 3,4-dihydro-2H-pyran (4.81 g, 56 mmol) and the mixture was stirred at reflux for 24 h. The mixture was filtered and the filtrate was washed with water (2 × 10 ml), dried over sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give 6.8 g (44%) of a pale yellow solid (dichloromethane / methanol 93: 3).

(Iii) 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7,7-dimethyl-1- (tetrahydro-pyran-2-yl) -5,7-dihydro -1H-imidazo [4,5-f] indole-6-one

To a suspension of sodium hydride (0.57 g, 22.5 mmol) in toluene (20 ml) was added tert-butanol (0.88 g, 11.8 mmol) at 80 ° C. and the mixture was stirred for 2 hours. After cooling to room temperature, 2-acetyl-5-ethyl-7,7-dimethyl-1- (tetrahydro-pyran-2-yl) -5, in N, N-dimethylformamide (DMF) (12 ml), A small amount of 7-dihydro-1H-imidazo [4,5-f] indol-6-one (2 g, 5.63 mmol) and carbon disulfide (0.43 g, 5.63 mmol) was added in small portions and the mixture was stirred at room temperature. Stir for 30 minutes and finally at 80 ° C. for 30 minutes. After cooling to room temperature, water (20 ml) and ethyl acetate (15 ml) were added, the layers were separated and the aqueous layer was extracted with ethyl acetate (3 × 10 ml). The combined organic phases were washed with water (3 x 10 ml) and concentrated in vacuo to give 2.27 g (88%) of 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7, 7-dimethyl-l- (tetrahydro-pyran-2-yl) -5,7-dihydro-lH-imidazo [4,5-f] indol-6-one was obtained, which partially departed during the reaction. It became luxurious. It was used in the next step without further purification. MS: M = 460.1 (ESI +)

(Iii) 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indole -6-on

Crude 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7,7-dimethyl-1- (tetrahydro-pyran-2-yl) -5,7-dihydro- 1H-imidazo [4,5-f] indole-6-one (2.25 g, 4.9 mmol) and p-toluenesulfonic acid monohydrate (0.5 g, 2.6 mmol) were added to methanol (25 ml) and water (3 ml). Dissolved in and stirred under reflux for 3 hours. After cooling to room temperature, water (50 ml) was added and the mixture was extracted with ethyl acetate (3 x 50 ml). The combined organic layer was washed with water and concentrated in vacuo. The crude product was recrystallized from methanol to give 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7,7-dimethyl-5,7-dihydro-1H-imidazo [4, 5-f] indol-6-one (0.71 g, 39%) was obtained as a yellow solid.

B: final product

Example  1 to 43

Standard process:

1-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- Preparation of 2-one (Example 11)

5-methyl-1H-pyrazole-3-carboxylic acid (126 mg, 1 mmol) and 5,6-diamino- in a mixture of polyphosphoric acid (5 g) and phosphorus pentoxide (500 mg, 3.5 mmol) 1-isopropyl-1,3-dihydro-benzoimidazol-2-one (206 mg, 1 mmol) was heated to 160 ° C. for 6 hours. This mixture was poured into water (20 ml) and stirred until a precipitate formed. After filtration, the crude product was suspended in water and neutralized by the addition of aqueous ammonia (25%). The precipitate was collected, washed with water and dried in vacuo. Purification by silica chromatography (dichloromethane / methanol 95: 5) 1-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1, 2-d; 4,5-d '] diimidazol-2-one was obtained as a slightly yellowish solid. Yield 36 mg (12%).

Using the experimental conditions reported above and suitable starting materials, the following derivatives 1 to 43 were prepared:

Example  44:

5-ethyl-2- (5- Methoxy -1H- Pyrazole -3-yl) -7,7-dimethyl-5,7- Dehydro -3H- Imidazo [4,5-f] indole -6-on

5-methoxy-1H-pyrazole-3-carboxylic acid (86 mg, 0.61 mmol), 1-hydroxybenzotriazole hydrate (111 mg, 0.73 mmol) and triethylamine (253 μl, 184 mg, 1.82 mmol) is dissolved in N, N-dimethylformamide (DMF) (2 ml) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) dissolved in DMF (2 ml). ) (139 mg, 0.73 mmol) was added and then the reaction mixture was stirred at room temperature. After 1 hour, a solution of 5,6-diamino-1-ethyl-3,3-dimethyl-1,3-dihydro-indol-2-one in DMF (2 ml) is added and the reaction mixture is brought to room temperature. Allow to cool and stir at room temperature for 16 hours. The solvent was removed under reduced pressure and the residue was quenched with water (20 ml) and extracted with ethyl acetate (3 x 20 ml). Layers were washed with brine (15 ml), dried over sodium sulfate and evaporated. The residue was dissolved in ethanol (5 ml) and after addition of hydrochloric acid (10 M, 2 ml), it was stirred for 2 h under reflux. Evaporated with ethanol and the residue was adjusted to pH 9-10 with ammonium hydroxide. After addition of water (20 ml), the aqueous phase was extracted with ethyl acetate (3 x 20 ml). Layers were washed with brine (10 ml), dried over sodium sulfate and evaporated. The crude product was purified by silica gel column chromatography. Elution with ethyl acetate / n-heptane (9: 1) gave 56 mg (28%) of a near white solid.

Example  45:

5-ethyl-7,7-dimethyl-2- (5- Methylsulfanyl -1H- Pyrazole -3-yl) -5,7- Dehydro -1H- Imidazo [4,5-f] indole -6-on

Hydrazine monohydrate (0.92 g, 1.8 mmol) was added 2- (3,3-bis-methylsulfanyl-acryloyl) -5-ethyl-7,7-dimethyl-1- (tetra) in acetonitrile (15 ml). To a suspension of hydro-pyran-2-yl) -5,7-dihydro-1H-imidazo [4,5-f] indol-6-one (0.68 g, 1.81 mmol) was added and stirred for 24 hours. . After cooling to room temperature, the precipitate was collected and washed with acetonitrile and ether to give 0.5 g (81%) of a pale white powder.

List of References

Adams, R. R., et al., Trends Cell Biol. 11 (2001) 49-54

Bastin, R. J., et al., Organic Proc. Res. Dev. 4 (2000) 427-435

Bischoff, J.R., and Plowman, G.D., Trends Cell Biol. 9 (1999) 454-459

DE 34 17 643

DE 36 42 315

DE 37 01 277

Djuric, S.W., et al., J. Med. Chem. 43 (200) 2975-2981

EP 0 189 103

EP 0 318 902

EP 0 868 519

EP 1 051 500

Giet, R., and Prigent, C., J. Cell Sci. 112 (1999) 3591-3601

Harrington, E. A., et al., Nat. Med. 10 (2O04) 262-267

Hunter, T., Cell 50 (1987) 823-829

Isola, JJ., Et al., Am. J. Pathology 147 (1995) 905-911

Jia, Z. J., et al., Bioorg. Med. Chem. Lett. 12 (2002) 1651-1655

Mahata, P.K., et al., Tetrahedron 59 (20O3) 2631-2639

Martins, M.A.P., et al., Synthesis 15 (20O3) 2353-2357

Mertens, A., et al., J. Med. Chem. 30 (1987) 1279-1287

Nigg, E. A., Nat. Rev. Mol. Cell Biol. 2 (2001) 21-32

Ochi, H., et al., Chem. Pharm. Bull. 31 (1983) 1228-1234

Pruitt, J.R., et al., J. Med. Chem. 46 (20O3) 5298-5315

Sen, S., et al., J. Natl. Cancer Inst. 94 (2002) 1320-1329

Sewald, N., et al., Liebigs Ann. Chem. (1992) 947-952

Stahl, P.H., and Wermuth, G., (editors), Handbook of Pharmaceutical Salts, Verlag Helvetica Chimica Acta (VHCA), Zurich (2002)

Stanovnik, B., and Svete, J., Science of Synthesis 12 (2002) 15-225

Subramanyam, C, Synth. Commun. 25 (1995) 761-774

US 4,835,280A

US 4,954,498

US 5,212,186A

US 6,207,401

van Herk, T., et al., J. Med. Chem. 46 (2O03) 3945-3951

von der Saal, W., et al., J. Med. Chem. 32 (1989) 1481-1491

WO 00/44728

WO 00/47212

WO 01/21594

WO 01/21595

WO 01/21596

WO 01/21597

WO 01/55116

WO 01/77085

WO 02/057259

WO 02/059111

WO 02/059112

WO 02/062789

WO 02/066461

WO 02/068415

WO 02/22601

WO 02/22602

WO 02/22603

WO 02/22604

WO 02/22605

WO 02/22606

WO 02/22607

WO 02/22608

WO 02/50065

WO 02/50066

WO 02/96905

WO 03/035065

WO 03/077921

WO 03/078423

WO 03/078426

WO 03/078427

WO 04/000833

WO 04/005283

WO 04/032928

WO 95/19169

WO 95/23141

WO 97/42187

WO 99/06396

Claims (12)

Use of a compound of formula (I) and all pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of cancer: [Formula I]

[Wherein R ¹ is hydrogen, alkyl or —C (O) -alkyl; R ² is hydrogen, alkyl, cyano or halogen; R ³ is hydrogen, alkyl, (C ₃ -C ₆ ) -cycloalkyl, alkoxy or alkylsulfanyl; X is -C (O)-or -CH _2- ; Y is -NH-, -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- ; here R ⁴ is hydrogen or alkyl; R ⁵ is hydrogen or alkyl, or alternatively R ⁴ and R ⁵ together with the carbon atom to which they are attached form a cycloalkyl ring. Use of a compound according to formula I according to claim 1 for the manufacture of a medicament for the treatment of cancer: Wherein R ³ is hydrogen, alkyl, (C ₃ -C ₆ ) -cycloalkyl. Use of a compound according to formula I according to claim 1 or 2 for the manufacture of a medicament for the treatment of cancer: [Wherein X is -CH _2- ]. Use of a compound according to formula I according to claim 1 or 2 for the manufacture of a medicament for the treatment of cancer: Wherein X is -C (O)-. Use of a compound according to formula I according to claim 1 for the manufacture of a medicament for the treatment of cancer: 7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -3,5,6,7-tetrahydro-imidazo [4,5-f] indole; 1- [7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -6,7-dihydro-3H-imidazo [4,5-f] indol-5-yl] Ethanone; 8,8-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one; 2- (5-isobutyl-2H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one; 7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 2- (5-methyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H) -On; 2- (5-isobutyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H )-On; 6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazol-2-one; 2- (4,5-dimethyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 7,7-dimethyl-2- [5- (3-methyl-butyl) -1H-pyrazol-3-yl] -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On; 2- (5-ethyl-4-methyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ; 7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 2- (5-cyclopropyl-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 2- (5-isopropyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one; 8,8-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one; 8,8-dimethyl-2- (1H-pyrazol-3-yl) -1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one; 2- (5-cyclopropyl-1H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one 2- (5-isopropyl-2H-pyrazol-3-yl) -8,8-dimethyl-1,5,7,8-tetrahydro-imidazo [4,5-g] quinolin-6-one; 2- (2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentan-1 ', 7-imidazo [4,5-f] indole] -6 (3H) -one; 2- (5-isopropyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H )-On; 2- (5-propyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ', 7-imidazo [4,5-f] indole] -6 (3H) -On; 7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6-one ; 2- (5-cyclopropyl-2H-pyrazol-3-yl) -spiro-5,7-dihydro [cyclopentane-1 ′, 7-imidazo [4,5-f] indole] -6 (3H )-On; 3-methyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole-2 -On; 3-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- 2-one; 5-ethyl-7,7-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5,7,7-trimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; 2- (5-isobutyl-2H-pyrazol-3-yl) -5,7,7-trimethyl-5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5,7,7-trimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5,7,7-trimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; Compounds with acetic acid; 5-isopropyl-7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On; 5-isopropyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On; 7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5-propyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ; 7,7-dimethyl-5-propyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5-ethyl-7,7-dimethyl-2- (5-trifluoromethyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole- 6-one; 5-isopropyl-7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole -6-one; 7,7-dimethyl-5-propyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole- 6-one; 5,7,7-trimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole-6 -On; 5-ethyl-2- (5-methoxy-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; And 5-ethyl-7,7-dimethyl-2- (5-methylsulfanyl-1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On. Compounds according to formula (I) and all pharmaceutically acceptable salts thereof: [Formula I]

[Wherein R ¹ is alkyl or —C (O) -alkyl; R ² is hydrogen, alkyl, cyano or halogen; R ³ is hydrogen, alkyl, (C ₃ -C ₆ ) -cycloalkyl, alkoxy or alkylsulfanyl; X is -C (O)-or -CH _2- ; Y is -NH-, -CH ₂ -CR ⁴ R ^5- , -CR ⁴ R ⁵ -CH ₂ -or -CR ⁴ R ^5- ; here R ⁴ is hydrogen or alkyl; R ⁵ is hydrogen or alkyl, or alternatively R ⁴ and R ⁵ together with the carbon atom to which they are attached form a cycloalkyl ring. The compound of claim 6 selected from the group consisting of: 5-ethyl-7,7-dimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5,7,7-trimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-2- (5-isobutyl-2H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; 2- (5-isobutyl-2H-pyrazol-3-yl) -5,7,7-trimethyl-5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5,7,7-trimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5,7,7-trimethyl-2- (5-methyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-7,7-dimethyl-2- (1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one; 5-ethyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; Compounds with acetic acid; 5-isopropyl-7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On; 5-isopropyl-7,7-dimethyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6- On; 7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -5-propyl-5,7-dihydro-1H-imidazo [4,5-f] indol-6-one ; 7,7-dimethyl-5-propyl-2- (5-propyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indol-6-one ; 5-ethyl-7,7-dimethyl-2- (5-trifluoromethyl-1H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole- 6-one; 5-isopropyl-7,7-dimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole -6-one; 7,7-dimethyl-5-propyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole- 6-one; 5,7,7-trimethyl-2- (5-trifluoromethyl-2H-pyrazol-3-yl) -5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; 5-ethyl-2- (5-methoxy-1H-pyrazol-3-yl) -7,7-dimethyl-5,7-dihydro-3H-imidazo [4,5-f] indole-6- On; 5-ethyl-7,7-dimethyl-2- (5-methylsulfanyl-1H-pyrazol-3-yl) -5,7-dihydro-1H-imidazo [4,5-f] indole-6 -On; 3-methyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole-2 -On; 3-isopropyl-6- (5-methyl-1H-pyrazol-3-yl) -3,5-dihydro-1H-benzo [1,2-d; 4,5-d '] diimidazole- 2-one; And 1- [7,7-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -6,7-dihydro-3H-imidazo [4,5-f] indol-5-yl] -Ethanone. The compound of claim 6, further comprising: a compound as follows; [Wherein, R ¹ is alkyl; R ² is hydrogen or alkyl; X is -C (O)-; Y is -CR ⁴ R ^5- . The compound of claim 6, wherein [Wherein, R ¹ is alkyl; R ² is hydrogen or alkyl; R ³ is hydrogen, alkyl or (C ₃ -C ₆ ) -cycloalkyl; X is -C (O)-; Y is -CR ⁴ R ^5- . As a process for preparing the compound of formula (I) as follows: Wherein R ¹ is alkyl or -C (O) -alkyl; a) with a compound of Formula II: [Formula II]

Wherein R ¹ is alkyl or —C (O) -alkyl, X and Y are as defined in formula (I) above, By reacting a compound of formula III: [Formula III]

[Wherein A is -OH, -Cl, -H or -OMe, R ² and R ³ are the same as defined in Formula I above], Provided is a compound of Formula I: [Formula I]

[Wherein R ¹ is alkyl or —C (O) -alkyl, R ² , R ³ , X and Y are the same as defined in Formula I above; b) isolating the compound of formula I from the reaction mixture and converting it to a pharmaceutically acceptable salt, if required. 10. A medicament comprising as an active ingredient at least one compound according to any one of claims 6 to 9 and a pharmaceutically acceptable adjuvant. A pharmaceutical for the treatment of cancer comprising as an active ingredient at least one compound according to any one of claims 6 to 9 and a pharmaceutically acceptable adjuvant.